Matthew Davids, MD
Enriched profileChief, Division of Lymphoma, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Matthew Davids is Chief, Division of Lymphoma, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 653 publications with 18,375 citations (h-index 61); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Matthew Davids, MD, is Chief, Division of Lymphoma, Dana-Farber Cancer Institute. The public record shows 653 publications with 18,375 citations (h-index 61), centered on Leukemia (AML/ALL/CML/CLL), Lymphoma, MDS / MPN. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 28 companies, 3 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Leukemia (AML/ALL/CML/CLL)
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 28 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 43 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Sponsor: Massachusetts General Hospital
- Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Sponsor: Dana-Farber Cancer Institute
- Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 18 Oct 2026
28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year20255 payments$14,945openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202516 payments$14,715openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202510 payments$11,940openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Calquence34%Jaypirca25%Brukinsa21%Tasigna21%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
Dana-Farber Cancer Inst
FY2026$403,271R01CA266298 - Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
Dana-Farber Cancer Inst
FY2025$403,340R01CA266298
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up.
American journal of hematology
Letter2026 - A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.
Blood advances
Clinical Trial2026 - BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
Journal of clinical oncology
Editorial2026
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/matthew-davids-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/drmdavids
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/matthew-s-davids-md-mmsc-9098b6197
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Matthew-S-Davids-35925527
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/DrMDavids
Mentions by others
where others cite or feature them- Other
cllsociety.org/2025/07/cll-societys-2025-clinical-scholar-award-dr-matt-davids
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cllsociety.org ↗ - Other
vjhemonc.com/speaker/matthew-davids
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - X / Twitter
x.com/DanaFarber/status/2055619273037394068
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile: Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Doximity
Doximity public profile listing Boston, MA oncology practice
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- A.B. cum laude
Chemistry, Harvard College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - M.D. cum laude
Yale University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - M.M.Sc. (Master of Medical Science)
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Chief
Division of Lymphoma, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Leader
Lymphoma Program, Harvard Cancer Consortium (Dana-Farber/Harvard Cancer Center)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Director of Clinical Research
Division of Lymphoma, Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cllsociety.org ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cllsociety.org ↗
Secondary affiliations
appointments beyond the home institution- Brigham and Women's Hospital
attending physician, inpatient hematologic malignancies service
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- Interviewed on Good Morning America about lymphoma
following actor Sam Neill's blood cancer diagnosis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →defycancer.dana-farber.org ↗ - Healthcare Unfiltered podcast
Episode 210: "CLL Updates and the Venetoclax Story"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Frank Hodi, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center